An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet

NCT01342198 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Pregabalin controlled release, 330 mg
DRUG: Pregabalin controlled release, 330 mg
DRUG: erythromycin

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.